MR Cancer Group
Our work focuses on development of magnetic resonance (MR) technology in identification of the functional and metabolic changes that precede anatomic evidence of cancer disease, tracking gene expression, studying drug delivery and response, and monitoring basic cellular processes.
|
The main goal is to develop metabolic, vascular and molecular imaging to assess therapeutic effects to be translated into the clinic. |
|
|
Aims at developing metabolic, vascular and molecular imaging for individual patient handling and treatment. |
|
|
The main goal using MR Metabolomics is to evaluate the clinical value of HR MAS for different kinds of cancer (breast, brain, prostate, colon and cervix), and by that establish HR MAS for predicting metastatic potential and choice of treatment. |
|
|
|
|
News and Events
PhD, postdoctoral fellow and research assistant positions in medical magnetic resonance technology at Department of Circulation and Medical Imaging Faculty of Medicine, Norwegian University of Science and Technology (NTNU). Deadline for applications: 28th February 2012. More details here
Contact Information
Ingrid S. Gribbestad
Professor
Telefon: 73863843
Mobil: 93059103
MR Cancer group is located at the MR center at St. Olavs Hospital in Trondheim, Norway. It is a part of Department of Circulation and Medical Imaging at the Faculty of Medicine, Norwegian University of Science and Technology (NTNU).
Recent publications
Giskeodegard GF, Lundgren S, Sitter B, Fjosne HE, Postma G, Buydens LM, Gribbestad IS, Bathen TF. Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers. NMR Biomed. 2012. Epub 2012/03/13. doi: 10.1002/nbm.2798. PubMed PMID: 22407957.
Cao MD, Döpkens M, Krishnamachary B, Vesuna F, Gadiya MM, Lønning PE, Bhujwalla ZM, Gribbestad IS, Glunde K. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed. 2012 Jan 26. doi: 10.1002/nbm.2766. [Epub ahead of print]
